Innate Pharma SA cash flow statement

In fiscal 2025, Innate Pharma SA's operations generated −$59.6m of cash; it spent $158,287 on capital projects, leaving free cash flow of −$59.8m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Innate Pharma SA: cash flow statement, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−54	−38	39	−59	−69	−20	−35	−7	−60
Depreciation and amortisation	5	9	15	11	5	5	6	2	2
Stock-based pay	11	3	4	3	3	4	5	4	3
Capital spending	3	1	1	1	1	1	0	0	0
Free cash flow	−58	−39	38	−60	−70	−21	−36	−8	−60
Free cash flow after stock pay	−69	−43	33	−63	−73	−25	−40	−12	−63

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CRBU vs IPHA IPHA vs RLAY IPHA vs IRD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Innate Pharma SA's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Innate Pharma SA.